Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good post Solantey. You always have something worthwhile to contribute wherever you post.
Many people questioned the short time period between the Adcom date and the PDUFA date when they announced the Adcom date being so close. This makes more sense.
They were up against it financially already, so what is a 3 month delay going to do to it now? Go to the well one more time?
I don’t understand how they can say it didn’t have as much efficacy as injected insulin, yet they say it was non-inferior? Makes no sense.
Whats the price on those Lincoln Park shares at $10.25m?
Breakout today on high volume. This is the real deal.
OK firefighter1, you talked me into it.
I spent some time on it today and these were my first impressions:
Shares already high for early stage company.
Impressive insider buying last 12 months.
Who or what is "X-Master"? Can't find anything on it.
The IND seems to have been repeatedly pushed back. Sounds like they will be lucky to get it filed by end of the year, if the final pre-clinical study results are due "end of 2014".
Spent 5 minutes on this new board and that's 5 minutes of my life I'll never get back.
I'm waiting for funding news too. The price broke trend line support late Feb/early March, so I expect it to drift lower until news.
I bought in the Fall of 2012 and am in no rush to sell. Like they say, "Let your winners run". I'll sell somewhere over $40- where many finally see it as more than a "spec play", LOL...
But seriously, I want to stick around to see how it does treating Alzheimer's too. That could add another major chunk to it.
Any traders want to speculate on the pattern of trading we've seen with this one? Looks to be market makers only here, creating strange price movements on low volume orders.
LOL, lets not get too excited that it did OK in Ph 1. It was a safety trial and if they used Cream O Wheat or Soy powder they'd get the same result. Plenty of room for optimism here though.
Thanks for bringing this to my attention.
Are you aware that Abbott and Gilead have Hep C drugs in trials that are doing very well? Better find another indication to bet on. Hep C is a crowded field and efficacy rates are excellent with whats out there.
http://www.reuters.com/article/2013/12/10/us-abbvie-study-hepatitisc-idUSBRE9B90KL20131210
http://news.medill.northwestern.edu/chicago/news.aspx?id=209158
If they had $750M cash, that would still be $1.00/share in cash, LOL.
Yes, there is valuable info here but we have to wade through too much irrelevant nonsense/time-wasting crap to find it.
Volume precedes price. watch the volume.
I agree. I stopped following this board for lack of news yes, but also a big waste of my time talking about nothing.
Yes, that interviewer was painfully unprepared. When he opened with the remark about Gerald's "brother" instead of father, I knew he took all of 2 minutes to prepare for it.
I can see the board needs something else to focus on today, so here's something new to chew on.
"The next step is to establish long-term analytical performance to support commercial launch in 2015."
Is anyone else troubled by the 7 year follow up study of the 88 patients from the ph 1 trial? It seems it would delay a partnership deal for LymPro. How do they pursue a commercial launch in 2015 with a 7 year study ongoing? I would think any buyer will point to the need for LT data and/or use it as leverage for a bigger discount. What am I missing?
"When the time is right". This is much different from their recent presentation where it stated plans to uplist in Q1. They seemed to have backed off on this plan.
A new biomarker for MD?
"..researchers at McMaster University in Canada have found that any of these types of damage can be detected by measuring the biomarker protein Xin.
In patients with healthy muscle tissue, Xin is undetectable, according to a study to be published in the American Journal of Pathology in December. But Xin starts to show up when there is muscle damage, the study shows, and to the degree that the damage occurs".
Read more: Protein in damaged tissue could be biomarker for muscular dystrophy - FierceBiomarkers http://www.fiercebiomarkers.com/story/protein-damaged-tissue-could-be-biomarker-muscular-dystrophy/2013-11-12#ixzz2kXeHF4iW
Don't know about $1100, but the chart for SAND shows a bearish formation with support at $4.75. The GDX and $HUI charts are very similar to each other, but slightly less bearish than SAND's. Can't say what the catalyst could be for this though in such a manipulated market.
Wow, this one surprised me. No position, was waiting until after results were announced and dilution, but was optimistic. What a minefield biotech is.
Wait for just ONE proof of concept trial validation for ONE indication before throwing money at this one.
Be aware that the biotech index (BTK) broke its long term trend line yesterday and closed below it again today. That's why many biotechs are selling off. Traders are lightening up. Be careful.
Imagine how many shares you will be able to buy when it goes to a buck! Back up the truck, right?
Get ready for a surge in QE bond buying. Two Fed officials wrote that they want the 6.5% unemployment threshold lowered. This will give an excuse to continue the monthly buying and put off tapering.
http://www.bloomberg.com/news/2013-11-06/u-s-economy-slack-justifies-stimulus-top-fed-staff-papers-show.html
They recently had a court decision (plaintiff in patent infringement case) that went against them on their patent for the test. The judge said the patent was based on a natural process, so it can't be patented. Seems like she doesn't understand the patent was for a way to quantify the natural process. They are appealing the decision.
This is a situation of good product, but not necessarily a good investment.
Good news? They are jettisoning things to keep the plane up and buy them time before it crashes. They are not doing it because things are going well. They are doing it because they are in trouble.
Watching the action here reminds me of Norman Bates in Psycho. Mom's long gone "Norman". You're in denial.
I'm seeing an effect on other diagnostic test companies taking a hit today due to the surprising ruling against SQNM when a judge declared their Down's Syndrome diagnostic patent invalid last thurs/friday. She said it was invalid because it used a natural process so its not patentable. It seems she didn’t know the difference between the natural process and a unique way to quantify that process with a diagnostic test. Anyway it will be appealed. Trovagene took a big hit today too, down 10%.
AMBS better get going on MANF before stem cell therapy eats their lunch:
http://www.hispanicbusiness.com/2013/11/4/mapcs_bring_lasting_improvements_after_brain.htm
Tweet this morning posted by Jason Napodano:
"I'm thinking data on Z160 the week of the 18th. Several smart "CNS people" have told me Z160 will fail, so trade wisely people!"
"CNS" is central nervous system.
You seem to be having a problem understanding my point. I'm just asking why the Powerpoint presentation was removed from the site. Why is that so hard to understand? It serves a different purpose than the 10-Q, if only to consolidate main points of discussion. If they were not useful than no one would post PP's and they just say "read the 10-Q" but they don't. There is a reason its gone, and I'm asking why.
I don't mean the 10-Q. I mean the Powerpoint Presentation that was posted on 9/14. Its gone now.
Amorfix would be a good acquisition for someone like AMBS for their diagnostic tests. Not sure about some of their tests, but the one for ALS is promising.
http://www.amorfix.com/als_diagnostic.php
Pig worms (Trichuris suis; TSO) do not live long in the human gut, so why did they go with them and not the human whip worm (Trichuris trichiura)?
I would think efficacy would drop off faster with pigworms (porcine) than its human counterpart, if it was within the 12 or 24 week trial period. Could this be why the recent trial results did not reach statistical significance? From an article descibing the difference between the two:
"..Clinical trials on helminthic therapy are particularly difficult to arrange because helminths are live pathogens and have not been officially approved as therapeutic agents by any governmental agency, although the U.S. Food and Drug Administration has granted pig whipworm (Trichuris suis) the status of Investigational New Drug. In contrast to human whipworm (Trichuris trichiura), the porcine variety cannot survive inside the human gut for very long."
http://www.scientificamerican.com/article.cfm?id=helminthic-therapy-mucus&WT.mc_id=SA_WR_20101207
Anyone notice CNDO took down the presentation on their website? It was used for the Sept conference, so it not really dated material.